Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Phathom Pharmaceuticals, Inc. (PHAT)
USD11.21
+0.30 (+2.72%)
US NASDAQ Healthcare Biotechnology
Address
100 Campus Drive 7932
Florham Park, NJ, US
Florham Park, NJ, US
CEO
Steven L. Basta
Website
phathompharma.com
IPO
2019-10-25
CIK 1783183 ISIN US71722W1071
Description
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD11.21
+0.30 (+2.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.49
Float Shares
49.81M
Free Float %
62.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.54% | +2.12% | -1.10% | +4.24% | -15.62% | -24.47% | +278.55% | -0.48% | -63.14% | -49.07% | -49.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
11.21
Low
18.00
+60.5%
Consensus
24.67
+120.0%
Median
28.00
+149.7%
High
28.00
+149.7%
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 2 |
23.00
+105.1%
|
| Last Year | 7 |
22.57
+101.3%
|
| All Time | 16 |
24.63
+119.7%
|
Quality scores
Altman Z-Score
-5.82
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+216.9% ★ Q1'26: +104.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+42.7% ★ Q1'26: +71.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-137.1% Q1'26: -26.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-91.4% Q1'26: -26.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +12.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.4% Q1'26: +14.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 3 EPS Ana. |
Dec 2027 7 Rev. Ana. 3 EPS Ana. |
Dec 2028 9 Rev. Ana. 7 EPS Ana. |
Dec 2029 4 Rev. Ana. 2 EPS Ana. |
Dec 2030 4 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
682.0K
est: 2.59M (-73.7%)
|
55.25M
est: 50.50M (+9.4%)
|
175.11M
est: 174.50M (+0.3%)
|
334.03M
332.35M – 336.77M
+91.4% YoY
|
539.95M
528.90M – 561.11M
+61.6% YoY
|
755.07M
755.07M – 755.07M
+39.8% YoY
|
904.79M
875.01M – 977.83M
+19.8% YoY
|
1.02B
986.60M – 1.10B
+12.8% YoY
|
| EBITDA |
-159.05M
est: -451.8K (-35,102.6%)
|
-261.52M
est: -9.19M (-2,745.5%)
|
-159.35M
est: -31.76M (-401.7%)
|
-60.79M
-61.29M – -60.49M
-91.4% YoY
|
-98.27M
-102.12M – -96.26M
-61.6% YoY
|
-137.42M
-137.42M – -137.42M
-39.8% YoY
|
-164.68M
-177.97M – -159.25M
-19.8% YoY
|
-185.68M
-200.67M – -179.56M
-12.8% YoY
|
| EBIT |
-159.62M
est: -453.7K (-35,083.9%)
|
-262.32M
est: -9.23M (-2,742.8%)
|
-159.99M
est: -31.89M (-401.7%)
|
-61.04M
-61.54M – -60.73M
-91.4% YoY
|
-98.66M
-102.53M – -96.64M
-61.6% YoY
|
-137.97M
-137.97M – -137.97M
-39.8% YoY
|
-165.33M
-178.68M – -159.89M
-19.8% YoY
|
-186.41M
-201.46M – -180.28M
-12.8% YoY
|
| Net Income |
-201.59M
est: -326.01M (+38.2%)
|
-334.33M
est: -398.02M (+16.0%)
|
-221.25M
est: -237.33M (+6.8%)
|
-40.71M
-43.62M – -37.79M
+82.8% YoY
|
90.22M
83.76M – 96.68M
+321.6% YoY
|
239.34M
126.57M – 366.36M
+165.3% YoY
|
288.45M
276.10M – 318.72M
+20.5% YoY
|
343.13M
328.45M – 379.15M
+19.0% YoY
|
| SGA |
117.93M
est: 94.30M (+25.1%)
|
290.66M
est: 1.84B (-84.2%)
|
279.72M
est: 6.34B (-95.6%)
|
12.14B
12.08B – 12.24B
+91.4% YoY
|
19.63B
19.23B – 20.40B
+61.6% YoY
|
27.45B
27.45B – 27.45B
+39.8% YoY
|
32.89B
31.81B – 35.55B
+19.8% YoY
|
37.09B
35.87B – 40.08B
+12.8% YoY
|
| EPS |
-3.93
est: -4.46 (+11.9%)
|
-5.29
est: -5.29 (+0.1%)
|
-3.03
est: -3.16 (+4.0%)
|
-0.54
-0.60 – -0.52
+82.8% YoY
|
1.20
1.15 – 1.33
+321.6% YoY
|
2.72
1.74 – 5.02
+126.9% YoY
|
3.96
3.79 – 4.37
+45.3% YoY
|
4.71
4.50 – 5.20
+19.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-86.81M
OE per share TTM
-1.17
Owner's Yield
-8.66%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
8.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
98.10M
Insider transactions (90d)
0
Beneficial owners (>5%)
44
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | James N. Topper | 8.42M | 21.50% | 17.6K | 8.41M | 17.6K | 8.41M | IN | — | 2022-09-26 | ↗ |
| 2 | Patrick J. Heron | 8.42M | 21.50% | 14.9K | 8.41M | 14.9K | 8.41M | IN | — | 2022-09-26 | ↗ |
| 3 | Takeda Pharmaceutical Company Limited | 7.46M | 19.20% | 7.46M | — | 7.46M | 10.00 | CO | Japan | 2021-11-12 | ↗ |
| 4 | FHMLS IX, L.L.C. | 5.83M | 14.90% | — | 5.83M | — | 5.83M | OO | — | 2022-09-26 | ↗ |
| 5 | FHMLS IX, L.P. | 5.83M | 14.90% | — | 5.83M | — | 5.83M | PN | — | 2022-09-26 | ↗ |
| 6 | Frazier Life Sciences IX, L.P. | 5.83M | 14.90% | — | 5.83M | — | 5.83M | PN | — | 2022-09-26 | ↗ |
| 7 | 2. | 3.83M | 12.30% | — | 3.83M | — | 3.83M | HC, IN | Delaware | 2021-02-16 | ↗ |
| 8 | (1) BlackRock, Inc. | 3.12M | 5.20% | 3.06M | — | 3.06M | — | HC | Delaware | 2024-11-12 | ↗ |
| 9 | Abingworth LLP | 2.94M | 6.70% | — | 2.94M | — | 2.94M | PN | England and Wales | 2023-03-09 | ↗ |
| 10 | CG Subsidiary Holdings L.L.C. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | OO | England and Wales | 2023-03-09 | ↗ |
| 11 | Carlyle Genesis UK LLC | 2.94M | 6.70% | — | 2.94M | — | 2.94M | OO | England and Wales | 2023-03-09 | ↗ |
| 12 | Carlyle Holdings I GP Inc. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | CO | England and Wales | 2023-03-09 | ↗ |
| 13 | Carlyle Holdings I GP Sub L.L.C. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | OO | England and Wales | 2023-03-09 | ↗ |
| 14 | Carlyle Holdings I L.P. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | PN | England and Wales | 2023-03-09 | ↗ |
| 15 | Carlyle Investment Management L.L.C. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | OO | England and Wales | 2023-03-09 | ↗ |
| 16 | TC Group, L.L.C. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | OO | England and Wales | 2023-03-09 | ↗ |
| 17 | The Carlyle Group Inc. | 2.94M | 6.70% | — | 2.94M | — | 2.94M | CO | England and Wales | 2023-03-09 | ↗ |
| 18 | Company, L.P. | 2.41M | 5.81% | — | 2.41M | — | — | PN | Delaware | 2022-09-23 | ↗ |
| 19 | Deerfield Mgmt, L.P. | 2.41M | 5.81% | — | 2.41M | — | — | PN | Delaware | 2022-09-23 | ↗ |
| 20 | Deerfield Partners, L.P. | 2.41M | 5.81% | — | 2.41M | — | — | PN | Delaware | 2022-09-23 | ↗ |
| 21 | James E. Flynn | 2.41M | 5.81% | — | 2.41M | — | — | IN | Delaware | 2022-09-23 | ↗ |
| 22 | Albert Cha | 2.08M | 5.30% | — | 2.08M | — | 2.08M | IN | — | 2022-09-26 | ↗ |
| 23 | FHMLSP, L.L.C. | 2.08M | 5.30% | — | 2.08M | — | 2.08M | OO | — | 2022-09-26 | ↗ |
| 24 | FHMLSP, L.P. | 2.08M | 5.30% | — | 2.08M | — | 2.08M | PN | — | 2022-09-26 | ↗ |
| 25 | Frazier Life Sciences Public Fund, L.P. | 2.08M | 5.30% | — | 2.08M | — | 2.08M | PN | — | 2022-09-26 | ↗ |
| 26 | James Brush | 2.08M | 5.30% | — | 2.08M | — | 2.08M | IN | — | 2022-09-26 | ↗ |
| 27 | 98-0557567 | 2.07M | 6.60% | 1.90M | — | 2.07M | — | IA, HC | Bermuda | 2022-02-10 | ↗ |
| 28 | The Vanguard Group - 23-1945930 | 1.93M | 6.14% | — | — | — | 46.0K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 29 | Avidity Capital Partners (GP) LLC | 1.90M | 6.00% | — | 1.90M | — | 1.90M | OO | — | 2022-02-14 | ↗ |
| 30 | Avidity Capital Partners Fund (GP) LP | 1.90M | 6.00% | — | 1.90M | — | 1.90M | PN, OO | — | 2022-02-14 | ↗ |
| 31 | Avidity Partners Management (GP) LLC | 1.90M | 6.00% | — | 1.90M | — | 1.90M | OO | — | 2022-02-14 | ↗ |
| 32 | Avidity Partners Management LP | 1.90M | 6.00% | — | 1.90M | — | 1.90M | IA, PN | — | 2022-02-14 | ↗ |
| 33 | David Witzke | 1.90M | 6.00% | — | 1.90M | — | 1.90M | IN | — | 2022-02-14 | ↗ |
| 34 | Michael Gregory | 1.90M | 6.00% | — | 1.90M | — | 1.90M | IN | — | 2022-02-14 | ↗ |
| 35 | EIN #00-0000000 | 1.84M | 5.90% | — | 1.84M | — | 1.84M | IA, HC | Jersey, Channel Islands | 2022-02-10 | ↗ |
| 36 | 1,687,721 | 1.69M | 5.40% | 1.69M | — | 1.69M | — | IN | — | 2021-02-11 | ↗ |
| 37 | 1,505,945 | 1.51M | 4.80% | 1.51M | — | 1.51M | — | IN | — | 2021-02-11 | ↗ |
| 38 | Abingworth Bioventures 8 LP | 1.50M | 3.40% | — | 1.50M | — | 1.50M | PN | England and Wales | 2023-03-09 | ↗ |
| 39 | Abingworth Bioventures VII LP | 1.44M | 3.30% | — | 1.44M | — | 1.44M | PN | England and Wales | 2023-03-09 | ↗ |
| 40 | Daniel Estes | 495.3K | 1.30% | — | 495.3K | — | 495.3K | IN | — | 2022-09-26 | ↗ |
| 41 | FHMLS XI, L.L.C. | 495.3K | 1.30% | — | 495.3K | — | 495.3K | OO | — | 2022-09-26 | ↗ |
| 42 | FHMLS XI, L.P. | 495.3K | 1.30% | — | 495.3K | — | 495.3K | PN | — | 2022-09-26 | ↗ |
| 43 | Frazier Life Sciences XI, L.P. | 495.3K | 1.30% | — | 495.3K | — | 495.3K | PN | — | 2022-09-26 | ↗ |
| 44 | Tadataka Yamada | — | 0.00% | — | — | — | — | IN | — | 2022-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-163 vs prev Q
New positions
2
Closed positions
160
Increased
9
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 86.8K +86.8K (+100.0%) | 1.44B +1.4B (+100.0%) | 0.12% +0.118 pp | 0.57% +0.568 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 2 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 12.47M +— (+0.0%) | 206.82M +60.1M (+41.0%) | 16.99% -0.218 pp | 5.55% +1.158 pp | USD12.42 +33.6% | 16 qtrs — |
| 3 | MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 7.46M +— (+0.0%) | 123.84M +36.0M (+41.0%) | 10.17% -0.131 pp | 14.83% +3.029 pp | USD16.82 -1.4% | 25 qtrs — |
| 4 | INVESCO LTD. | 3.92M +55.5K (+1.4%) | 65.04M +19.5M (+43.0%) | 5.34% +0.008 pp | 0.01% +0.003 pp | USD20.89 -20.6% | 25 qtrs — |
| 5 | BLACKROCK, INC. | 3.56M +153.2K (+4.5%) | 58.99M +18.9M (+47.3%) | 4.84% +0.149 pp | 0.00% +0.000 pp | USD16.85 -1.5% | 6 qtrs — |
| 6 | CARLYLE GROUP INC. | 3.50M +— (+0.0%) | 57.98M +16.9M (+41.2%) | 4.76% -0.061 pp | 0.43% -0.519 pp | USD8.29 +100.1% | 12 qtrs — |
| 7 | VANGUARD GROUP INC | 3.18M -38.4K (-1.2%) | 52.71M +14.9M (+39.3%) | 4.33% -0.109 pp | 0.00% +0.000 pp | USD18.82 -11.8% | 25 qtrs — |
| 8 | ENSIGN PEAK ADVISORS, INC | 2.35M -151.3K (-6.0%) | 39.02M +9.6M (+32.4%) | 3.20% -0.250 pp | 0.07% +0.021 pp | USD19.22 -13.7% | 25 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 2.08M -3.0M (-59.0%) | 34.54M -25.3M (-42.2%) | 2.84% -4.175 pp | 0.01% -0.011 pp | USD10.55 +57.3% | 14 qtrs — |
| 10 | NEA MANAGEMENT COMPANY, LLC | 1.96M +— (+0.0%) | 32.52M +9.4M (+41.0%) | 2.67% -0.034 pp | 1.66% +0.392 pp | USD12.51 +32.6% | 11 qtrs — |
| 11 | 683 CAPITAL MANAGEMENT, LLC | 1.79M -35.4K (-1.9%) | 29.61M +8.2M (+38.2%) | 2.43% -0.080 pp | 1.29% +0.169 pp | USD9.44 +75.7% | 17 qtrs — |
| 12 | CATALYS PACIFIC, LLC | 1.43M +261.9K (+22.4%) | 23.71M +10.0M (+72.6%) | 1.95% +0.336 pp | 7.63% +3.725 pp | USD12.97 +27.9% | 9 qtrs — |
| 13 | WASATCH ADVISORS LP | 1.33M -205.5K (-13.4%) | 22.09M +4.0M (+22.1%) | 1.81% -0.307 pp | 0.13% +0.034 pp | USD9.53 +74.1% | 6 qtrs — |
| 14 | GW&K INVESTMENT MANAGEMENT, LLC | 1.31M +162.3K (+14.2%) | 21.68M +8.2M (+60.9%) | 1.78% +0.201 pp | 0.19% +0.068 pp | USD19.36 -14.3% | 20 qtrs — |
| 15 | STATE STREET CORP | 1.15M +95.9K (+9.1%) | 19.07M +6.7M (+53.8%) | 1.57% +0.112 pp | 0.00% +0.000 pp | USD17.02 -2.5% | 25 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.07M -15.5K (-1.4%) | 17.81M +5.0M (+38.9%) | 1.46% -0.040 pp | 0.00% +0.000 pp | USD16.44 +0.9% | 25 qtrs — |
| 17 | PROPEL BIO MANAGEMENT, LLC | 740.9K +188.0K (+34.0%) | 12.29M +5.8M (+88.9%) | 1.01% +0.247 pp | 10.49% +3.980 pp | USD11.08 +49.7% | 9 qtrs — |
| 18 | CATALIO CAPITAL MANAGEMENT, LP | 699.0K -429.5K (-38.1%) | 11.60M -1.7M (-12.7%) | 0.95% -0.605 pp | 2.05% -0.406 pp | USD10.47 +58.5% | 3 qtrs — |
| 19 | DIVISADERO STREET CAPITAL MANAGEMENT, LP | 662.3K +662.3K (+100.0%) | 10.99M +11.0M (+100.0%) | 0.90% +0.902 pp | 0.51% +0.514 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 20 | MOORE CAPITAL MANAGEMENT, LP | 600.0K +— (+0.0%) | 9.95M +2.9M (+41.0%) | 0.82% -0.011 pp | 0.14% +0.046 pp | USD9.59 +73.0% | 3 qtrs — |
| 21 | SUMMITTX CAPITAL, L.P. | 517.8K +131.9K (+34.2%) | 8.59M +4.0M (+89.1%) | 0.71% +0.173 pp | 0.26% +0.071 pp | USD13.00 +27.6% | 2 qtrs — |
| 22 | CAPTION MANAGEMENT, LLC | 486.3K -513.7K (-51.4%) | 8.07M -3.7M (-31.5%) | 0.66% -0.717 pp | 0.06% -0.037 pp | USD10.94 +51.6% | 3 qtrs — |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 397.9K +32.0K (+8.7%) | 6.60M +2.3M (+53.3%) | 0.54% +0.037 pp | 0.00% +0.000 pp | USD17.10 -3.0% | 25 qtrs — |
| 24 | NEXT CENTURY GROWTH INVESTORS LLC | 393.8K +393.8K (+100.0%) | 6.53M +6.5M (+100.0%) | 0.54% +0.537 pp | 0.45% +0.454 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 25 | GOLDMAN SACHS GROUP INC | 392.0K +240.0K (+157.9%) | 6.50M +4.7M (+263.5%) | 0.53% +0.324 pp | 0.00% +0.001 pp | USD14.77 +12.3% | 18 qtrs — |
| 26 | JANE STREET GROUP, LLC | 384.8K +277.5K (+258.7%) | 6.38M +5.1M (+405.6%) | 0.52% +0.376 pp | 0.00% +0.001 pp | USD15.25 +8.8% | 2 qtrs — |
| 27 | NORTHERN TRUST CORP | 356.5K -1.1K (-0.3%) | 5.91M +1.7M (+40.5%) | 0.49% -0.008 pp | 0.00% +0.000 pp | USD19.85 -16.4% | 25 qtrs — |
| 28 | SIMPLIFY ASSET MANAGEMENT INC. | 321.9K +— (+0.0%) | 5.34M +1.6M (+41.0%) | 0.44% -0.006 pp | 0.09% +0.017 pp | USD8.54 +94.3% | 12 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 317.6K +262.3K (+474.3%) | 5.27M +4.6M (+709.5%) | 0.43% +0.356 pp | 0.00% +0.001 pp | USD15.37 +7.9% | 16 qtrs — |
| 30 | CITADEL ADVISORS LLC | 311.3K -197.4K (-38.8%) | 5.16M -822.9K (-13.7%) | 0.42% -0.278 pp | 0.00% 0.000 pp | USD11.77 +41.0% | 24 qtrs — |
| 31 | UBS GROUP AG | 304.4K -34.0K (-10.0%) | 5.05M +1.1M (+26.8%) | 0.41% -0.052 pp | 0.00% +0.000 pp | USD8.11 +104.6% | 14 qtrs — |
| 32 | STEPSTONE GROUP LP | 422.1K +— (+0.0%) | 4.97M +— (+0.0%) | 0.58% -0.007 pp | 2.66% +0.322 pp | USD32.10 -48.3% | 18 qtrs — |
| 33 | JPMORGAN CHASE & CO | 296.7K +159.7K (+116.6%) | 4.92M +3.3M (+205.4%) | 0.40% +0.215 pp | 0.00% +0.000 pp | USD22.06 -24.8% | 25 qtrs — |
| 34 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 277.0K +218.9K (+376.8%) | 4.60M +3.9M (+572.0%) | 0.38% +0.297 pp | 0.05% +0.047 pp | USD15.36 +8.0% | 7 qtrs — |
| 35 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 268.0K +— (+0.0%) | 4.45M +1.3M (+41.0%) | 0.37% -0.005 pp | 0.07% +0.019 pp | USD9.59 +73.0% | 3 qtrs — |
| 36 | D. E. SHAW & CO., INC. | 261.1K +261.1K (+100.0%) | 4.33M +4.3M (+100.0%) | 0.36% +0.356 pp | 0.00% +0.002 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 37 | BANK OF AMERICA CORP /DE/ | 259.0K +9.9K (+4.0%) | 4.30M +1.4M (+46.6%) | 0.35% +0.009 pp | 0.00% +0.000 pp | USD11.31 +46.7% | 25 qtrs — |
| 38 | BALYASNY ASSET MANAGEMENT L.P. | 207.1K -88.1K (-29.8%) | 3.44M -38.5K (-1.1%) | 0.28% -0.125 pp | 0.00% +0.000 pp | USD11.52 +44.0% | 7 qtrs — |
| 39 | AVIDITY PARTNERS MANAGEMENT LP | 206.1K -99.9K (-32.7%) | 3.42M -182.8K (-5.1%) | 0.28% -0.142 pp | 0.99% +0.166 pp | USD15.91 +4.3% | 17 qtrs — |
| 40 | BIRCHVIEW CAPITAL, LP | 195.0K +110.0K (+129.4%) | 3.24M +2.2M (+223.4%) | 0.27% +0.148 pp | 1.89% +1.139 pp | USD14.21 +16.7% | 3 qtrs — |
| 41 | NEWEDGE ADVISORS, LLC | 200.8K -700.0 (-0.3%) | 3.16M +930.3K (+41.7%) | 0.27% -0.005 pp | 0.01% +0.001 pp | USD11.77 +41.0% | 2 qtrs — |
| 42 | WOODLINE PARTNERS LP | 187.3K +— (+0.0%) | 3.11M +902.7K (+41.0%) | 0.26% -0.003 pp | 0.01% +0.002 pp | USD16.21 +2.3% | 11 qtrs — |
| 43 | AMERIPRISE FINANCIAL INC | 185.7K -368.8K (-66.5%) | 3.08M -3.4M (-52.8%) | 0.25% -0.512 pp | 0.00% -0.001 pp | USD11.06 +50.0% | 3 qtrs — |
| 44 | CAXTON ASSOCIATES LLP | 182.0K +143.4K (+371.8%) | 3.02M +2.6M (+565.0%) | 0.25% +0.195 pp | 0.06% +0.048 pp | USD15.57 +6.6% | 2 qtrs — |
| 45 | HUSSMAN STRATEGIC ADVISORS, INC. | 147.0K +147.0K (+100.0%) | 2.44M +2.4M (+100.0%) | 0.20% +0.200 pp | 0.59% +0.589 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 46 | GILDER GAGNON HOWE & CO LLC | 145.2K +56.6K (+64.0%) | 2.41M +1.4M (+131.1%) | 0.20% +0.076 pp | 0.03% +0.015 pp | USD15.07 +10.1% | 20 qtrs — |
| 47 | TREXQUANT INVESTMENT LP | 136.8K +58.6K (+75.0%) | 2.27M +1.3M (+146.7%) | 0.19% +0.079 pp | 0.02% +0.011 pp | USD13.84 +19.9% | 5 qtrs — |
| 48 | WELLINGTON MANAGEMENT GROUP LLP | 134.5K -11.9K (-8.1%) | 2.23M +508.3K (+29.5%) | 0.18% -0.019 pp | 0.00% +0.000 pp | USD11.77 +41.0% | 11 qtrs — |
| 49 | BANK OF NEW YORK MELLON CORP | 123.0K -4.4K (-3.5%) | 2.04M +540.7K (+36.1%) | 0.17% -0.008 pp | 0.00% +0.000 pp | USD16.97 -2.2% | 25 qtrs — |
| 50 | MORGAN STANLEY | 117.8K -137.8K (-53.9%) | 1.95M -1.1M (-35.0%) | 0.16% -0.192 pp | 0.00% 0.000 pp | USD10.11 +64.1% | 25 qtrs — |
| 51 | CAMPBELL & CO INVESTMENT ADVISER LLC | 115.3K +115.3K (+100.0%) | 1.91M +1.9M (+100.0%) | 0.16% +0.157 pp | 0.09% +0.092 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 52 | HENNION & WALSH ASSET MANAGEMENT, INC. | 115.0K +115.0K (+100.0%) | 1.91M +1.9M (+100.0%) | 0.16% +0.157 pp | 0.07% +0.066 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 53 | NUVEEN, LLC | 108.8K -1.3K (-1.1%) | 1.81M +509.8K (+39.3%) | 0.15% -0.004 pp | 0.00% +0.000 pp | USD6.53 +154.1% | 4 qtrs — |
| 54 | GROUP ONE TRADING, L.P. | 103.7K +99.4K (+2,340.8%) | 1.72M +1.7M (+3,340.3%) | 0.14% +0.135 pp | 0.00% +0.003 pp | USD16.39 +1.2% | 9 qtrs — |
| 55 | BARCLAYS PLC | 84.9K +27.1K (+46.8%) | 1.41M +362.7K (+34.7%) | 0.12% +0.036 pp | 0.00% +0.000 pp | USD13.94 +19.0% | 16 qtrs — |
| 56 | SWISS NATIONAL BANK | 84.0K +84.0K (+100.0%) | 1.39M +1.4M (+100.0%) | 0.11% +0.114 pp | 0.00% +0.001 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 57 | GSA CAPITAL PARTNERS LLP | 82.6K +12.4K (+17.6%) | 1.37M +544.0K (+65.8%) | 0.11% +0.016 pp | 0.12% +0.049 pp | USD12.49 +32.8% | 2 qtrs — |
| 58 | CREATIVE PLANNING | 80.8K +2.7K (+3.5%) | 1.34M +421.2K (+45.8%) | 0.11% +0.002 pp | 0.00% +0.000 pp | USD9.18 +80.7% | 12 qtrs — |
| 59 | WELLS FARGO & COMPANY/MN | 68.0K +14.4K (+26.8%) | 1.13M +496.9K (+78.7%) | 0.09% +0.019 pp | 0.00% +0.000 pp | USD11.30 +46.8% | 17 qtrs — |
| 60 | PENN MUTUAL ASSET MANAGEMENT, LLC | 62.8K +— (+0.0%) | 1.04M +302.7K (+41.0%) | 0.09% -0.001 pp | 0.62% -0.813 pp | USD13.61 +21.9% | 23 qtrs — |
| 61 | DARK FOREST CAPITAL MANAGEMENT LP | 62.2K +62.2K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.08% +0.085 pp | 0.05% +0.047 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 62 | TWO SIGMA INVESTMENTS, LP | 57.8K +57.8K (+100.0%) | 958.6K +958.6K (+100.0%) | 0.08% +0.079 pp | 0.00% +0.001 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 63 | AQR CAPITAL MANAGEMENT LLC | 54.4K +1.8K (+3.5%) | 903.3K +283.9K (+45.8%) | 0.07% +0.002 pp | 0.00% +0.000 pp | USD7.17 +131.4% | 5 qtrs — |
| 64 | RHUMBLINE ADVISERS | 52.1K -9.6K (-15.6%) | 864.2K +137.9K (+19.0%) | 0.07% -0.014 pp | 0.00% +0.000 pp | USD15.09 +9.9% | 25 qtrs — |
| 65 | STIFEL FINANCIAL CORP | 51.7K +31.8K (+160.0%) | 857.1K +623.2K (+266.5%) | 0.07% +0.043 pp | 0.00% +0.001 pp | USD12.81 +29.5% | 4 qtrs — |
| 66 | STRATOS WEALTH PARTNERS, LTD. | 50.3K +50.3K (+100.0%) | 834.5K +834.5K (+100.0%) | 0.07% +0.069 pp | 0.01% +0.009 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 67 | ALLIANCEBERNSTEIN L.P. | 49.4K +3.8K (+8.3%) | 819.4K +282.8K (+52.7%) | 0.07% +0.004 pp | 0.00% +0.000 pp | USD14.73 +12.6% | 23 qtrs — |
| 68 | VIRTUS INVESTMENT ADVISERS, INC. | 46.9K +2.6K (+5.9%) | 778.7K +257.2K (+49.3%) | 0.06% +0.003 pp | 0.21% +0.062 pp | USD6.85 +142.2% | 4 qtrs — |
| 69 | ENGINEERS GATE MANAGER LP | 44.3K +44.3K (+100.0%) | 734.2K +734.2K (+100.0%) | 0.06% +0.060 pp | 0.01% +0.009 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 70 | ADAR1 CAPITAL MANAGEMENT, LLC | 42.9K +— (+0.0%) | 711.7K +206.8K (+41.0%) | 0.06% -0.001 pp | 0.05% +0.005 pp | USD8.62 +92.5% | 6 qtrs — |
| 71 | SOUTHEAST ASSET ADVISORS INC. | 42.9K +42.9K (+100.0%) | 711.3K +711.3K (+100.0%) | 0.06% +0.058 pp | 0.07% +0.068 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 72 | NEW YORK STATE COMMON RETIREMENT FUND | 41.8K +31.0K (+287.7%) | 692.7K +566.0K (+446.5%) | 0.06% +0.042 pp | 0.00% +0.001 pp | USD17.97 -7.7% | 25 qtrs — |
| 73 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 40.1K +37.3K (+1,288.6%) | 666.0K +631.9K (+1,857.2%) | 0.05% +0.051 pp | 0.00% +0.001 pp | USD17.00 -2.4% | 25 qtrs — |
| 74 | XTX TOPCO LTD | 39.4K -15.2K (-27.8%) | 653.6K +11.2K (+1.7%) | 0.05% -0.022 pp | 0.02% -0.016 pp | USD10.33 +60.6% | 4 qtrs — |
| 75 | PRICE T ROWE ASSOCIATES INC /MD/ | 37.1K +5.2K (+16.1%) | 616.0K +240.0K (+63.8%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD10.39 +59.7% | 15 qtrs — |
| 76 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 34.7K +10.0K (+40.5%) | 575.7K +285.0K (+98.0%) | 0.05% +0.013 pp | 0.01% +0.004 pp | USD13.16 +26.1% | 2 qtrs — |
| 77 | LEGAL & GENERAL GROUP PLC | 34.2K +30.2K (+738.0%) | 568.2K +520.1K (+1,081.2%) | 0.05% +0.041 pp | 0.00% +0.000 pp | USD16.39 +1.2% | 25 qtrs — |
| 78 | DEUTSCHE BANK AG\ | 33.4K +3.8K (+12.9%) | 553.8K +205.7K (+59.1%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD14.51 +14.3% | 25 qtrs — |
| 79 | SCHONFELD STRATEGIC ADVISORS LLC | 30.9K +30.9K (+100.0%) | 513.4K +513.4K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.002 pp | USD16.59 +0.0% | 3 qtrs — |
| 80 | COMMONWEALTH EQUITY SERVICES, LLC | 30.9K +324.0 (+1.1%) | 513.3K +153.3K (+42.6%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD8.68 +91.1% | 7 qtrs — |
| 81 | UBS ASSET MANAGEMENT AMERICAS INC | 30.6K +30.6K (+100.0%) | 508.2K +508.2K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.000 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 82 | Y-INTERCEPT (HONG KONG) LTD | 30.5K +30.5K (+100.0%) | 505.8K +505.8K (+100.0%) | 0.04% +0.042 pp | 0.01% +0.011 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 83 | OCCIDENTAL ASSET MANAGEMENT, LLC | 29.9K +247.0 (+0.8%) | 496.4K +147.1K (+42.1%) | 0.04% 0.000 pp | 0.06% +0.016 pp | USD8.51 +94.9% | 15 qtrs — |
| 84 | TUDOR INVESTMENT CORP ET AL | 28.6K -5.5K (-16.2%) | 473.7K +72.5K (+18.1%) | 0.04% -0.008 pp | 0.00% +0.000 pp | USD11.77 +41.0% | 2 qtrs — |
| 85 | CITIGROUP INC | 28.5K +14.8K (+108.7%) | 472.1K +311.7K (+194.2%) | 0.04% +0.020 pp | 0.00% +0.000 pp | USD11.96 +38.7% | 25 qtrs — |
| 86 | QUEST PARTNERS LLC | 28.3K -26.3K (-48.3%) | 468.7K -173.9K (-27.1%) | 0.04% -0.037 pp | 0.03% -0.016 pp | USD10.68 +55.3% | 6 qtrs — |
| 87 | HRT FINANCIAL LP | 27.0K +4.5K (+19.9%) | 448.0K +183.0K (+69.1%) | 0.04% +0.006 pp | 0.00% +0.000 pp | USD12.57 +32.0% | 4 qtrs — |
| 88 | LOS ANGELES CAPITAL MANAGEMENT LLC | 33.4K +33.4K (+100.0%) | 444.9K +444.9K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.002 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 89 | METLIFE INVESTMENT MANAGEMENT, LLC | 25.8K +— (+0.0%) | 428.8K +124.6K (+41.0%) | 0.04% -0.001 pp | 0.00% +0.001 pp | USD16.15 +2.7% | 24 qtrs — |
| 90 | RAYMOND JAMES FINANCIAL INC | 24.4K +11.0K (+82.1%) | 404.6K +247.0K (+156.7%) | 0.03% +0.015 pp | 0.00% +0.000 pp | USD13.66 +21.4% | 5 qtrs — |
| 91 | ROYAL BANK OF CANADA | 22.6K -139.9K (-86.1%) | 374.0K -1.5M (-80.4%) | 0.03% -0.193 pp | 0.00% 0.000 pp | USD9.76 +70.0% | 20 qtrs — |
| 92 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 22.4K -48.9K (-68.6%) | 371.6K -467.3K (-55.7%) | 0.03% -0.068 pp | 0.00% -0.006 pp | USD10.60 +56.5% | 6 qtrs — |
| 93 | SUMMIT FINANCIAL WEALTH ADVISORS, LLC | 22.1K +— (+0.0%) | 367.4K +95.2K (+35.0%) | 0.03% 0.000 pp | 0.05% +0.010 pp | USD12.36 +34.2% | 6 qtrs — |
| 94 | ACADIAN ASSET MANAGEMENT LLC | 22.2K +22.2K (+100.0%) | 367.0K +367.0K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.001 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 95 | JAIN GLOBAL LLC | 21.7K +21.7K (+100.0%) | 360.6K +360.6K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.002 pp | USD16.59 +0.0% | 1 qtrs NEW |
| 96 | KERA CAPITAL PARTNERS, INC. | 24.3K -5.8K (-19.3%) | 331.6K -22.2K (-6.3%) | 0.03% -0.008 pp | 0.04% -0.012 pp | USD7.95 +108.7% | 5 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.63
Bullish
Ratio by volume
3.00
Bullish
Buys
13
Sells
8
Shares acquired
906.8K
Shares disposed
139.2K
Cash buys
—
Cash sales
—
Net activity
+767,623
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | Parikh Asit | Director | G-Gift | A | Common Stock | 40,000 | 0.00 | — | 120,500 | I | ↗ |
| 2026-02-27 | Breedlove Robert Charles | Officer | A-Award | A | Common Stock | 2,790 | 0.00 | — | 62,858 | D | ↗ |
| 2026-02-10 | Cook Anne Marie | Officer | A-Award | A | Common Stock | 3,461 | 0.00 | — | 90,195 | D | ↗ |
| 2026-02-10 | Basta Steven L | Director / Officer | A-Award | A | Common Stock | 12,362 | 0.00 | — | 379,592 | D | ↗ |
| 2026-01-23 | Parikh Asit | Director | G-Gift | D | Common Stock | 80,500 | 0.00 | — | 50,500 | D | ↗ |
| 2026-01-21 | Breedlove Robert Charles | Officer | F-InKind | D | Common Stock | 776 | 13.61 | 10.6K | 47,068 | D | ↗ |
| 2026-01-13 | Parikh Asit | Director | M-Exempt | A | Common Stock | 8,750 | 10.30 | 90.1K | 131,000 | D | ↗ |
| 2026-01-02 | Narula Sanjeev | Officer | A-Award | A | Common Stock | 82,715 | 0.00 | — | 226,715 | D | ↗ |
| 2026-01-02 | Cook Anne Marie | Officer | A-Award | A | Common Stock | 75,345 | 0.00 | — | 85,012 | D | ↗ |
| 2026-01-02 | Basta Steven L | Director / Officer | A-Award | A | Common Stock | 251,034 | 0.00 | — | 364,820 | D | ↗ |
| 2025-12-19 | Parikh Asit | Director | M-Exempt | D | Common Stock (Right to Buy) | 8,750 | 10.30 | 90.1K | 8,750 | D | ↗ |
| 2025-12-18 | Breedlove Robert Charles | Officer | F-InKind | D | Common Stock | 230 | 16.28 | 3.7K | 47,844 | D | ↗ |
| 2025-12-17 | Cook Anne Marie | Officer | F-InKind | D | Common Stock | 7,703 | 15.36 | 118.3K | 9,667 | D | ↗ |
| 2025-12-17 | Basta Steven L | Director / Officer | A-Award | A | Common Stock | 62,038 | 0.00 | — | 145,288 | D | ↗ |
| 2025-11-28 | Basta Steven L | Director / Officer | M-Exempt | D | Performance Shares | 90,000 | 0.00 | — | 180,000 | D | ↗ |
| 2025-11-03 | Breedlove Robert Charles | Officer | S-Sale | D | Common Stock | 524 | 13.51 | 7.1K | 47,407 | D | ↗ |
| 2025-10-06 | Narula Sanjeev | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 11.61 | 2.32M | 200,000 | D | ↗ |
| 2025-09-25 | Basta Steven L | Director / Officer | M-Exempt | A | Common Stock | 90,000 | 0.00 | — | 90,000 | D | ↗ |
| 2025-09-05 | Breedlove Robert Charles | Officer | S-Sale | D | Common Stock | 461 | 12.09 | 5.6K | 47,931 | D | ↗ |
| 2025-07-16 | Breedlove Robert Charles | Officer | S-Sale | D | Common Stock | 1,692 | 8.36 | 14.2K | 48,392 | D | ↗ |
| 2025-06-23 | Cook Anne Marie | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 9.47 | 1.99M | 210,000 | D | ↗ |
| 2025-06-03 | Topper James N | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 17,500 | 4.95 | 86.6K | 17,500 | D | ↗ |
| 2025-06-03 | Stenhouse Mark | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 30,000 | D | ↗ |
| 2025-06-03 | Parikh Asit | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 113,500 | D | ↗ |
| 2025-06-03 | KARBE FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 17,500 | 4.95 | 86.6K | 17,500 | D | ↗ |
| 2025-06-03 | FIELDS HEIDI | Director | A-Award | A | Stock Option (Right to Buy) | 17,500 | 4.95 | 86.6K | 17,500 | D | ↗ |
| 2025-06-03 | COLA MICHAEL F | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 39,798 | D | ↗ |
| 2025-05-21 | Topper James N | Director | P-Purchase | A | Common Stock | 3,780 | 3.86 | 14.6K | 59,403 | I | ↗ |
| 2025-05-19 | Breedlove Robert Charles | Officer | A-Award | A | Stock Option (Right to Buy) | 33,000 | 4.39 | 144.9K | 33,000 | D | ↗ |
| 2025-05-14 | Topper James N | Director | P-Purchase | A | Common Stock | 6,300 | 3.32 | 20.9K | 55,623 | I | ↗ |
| 2025-05-13 | Topper James N | Director | P-Purchase | A | Common Stock | 1,120 | 3.16 | 3.5K | 49,323 | I | ↗ |
| 2025-05-12 | Topper James N | Director | P-Purchase | A | Common Stock | 12,601 | 3.04 | 38.3K | 48,203 | I | ↗ |
| 2025-05-09 | Topper James N | Director | P-Purchase | A | Common Stock | 33,376 | 3.19 | 106.6K | 33,376 | I | ↗ |
| 2025-05-07 | Parikh Asit | Director | P-Purchase | A | Common Stock | 5,000 | 2.40 | 12.0K | 95,500 | D | ↗ |
| 2025-05-06 | Parikh Asit | Director | P-Purchase | A | Common Stock | 5,000 | 2.60 | 13.0K | 90,500 | D | ↗ |
| 2025-05-01 | Breedlove Robert Charles | Officer | — | — | Common Stock | 0 | 0.00 | — | 50,084 | D | ↗ |
| 2025-04-16 | Schroeder Theodore R | Director | A-Award | A | Common Stock (Right to Buy) | 35,000 | 4.23 | 148.1K | 35,000 | D | ↗ |
| 2025-04-07 | Henderson Molly | Officer | S-Sale | D | Common Stock | 3,678 | 4.55 | 16.7K | 89,868 | D | ↗ |
| 2025-04-03 | Basta Steven L | Director / Officer | A-Award | A | Performance Shares | 360,000 | 0.00 | — | 360,000 | D | ↗ |
| 2025-04-01 | Basta Steven L | Director / Officer | — | — | No securities are beneficially owned. | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-03-13 | Parikh Asit | Director | P-Purchase | A | Common Stock | 10,000 | 4.42 | 44.2K | 85,500 | D | ↗ |
| 2025-02-27 | Nabulsi Azmi | Officer | A-Award | A | Common Stock | 79,200 | 0.00 | — | 312,590 | D | ↗ |
| 2025-02-27 | Henderson Molly | Officer | A-Award | A | Common Stock | 72,000 | 0.00 | — | 165,546 | D | ↗ |
| 2025-02-27 | Curran Terrie | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 342,500 | 5.76 | 1.97M | 342,500 | D | ↗ |
| 2025-01-21 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 7,886 | 6.59 | 52.0K | 233,390 | D | ↗ |
| 2025-01-21 | Henderson Molly | Officer | S-Sale | D | Common Stock | 6,583 | 6.59 | 43.4K | 93,546 | D | ↗ |
| 2025-01-21 | Curran Terrie | Director / Officer | S-Sale | D | Common Stock | 19,109 | 6.59 | 125.9K | 360,465 | D | ↗ |
| 2024-12-19 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 1,118 | 8.00 | 8.9K | 239,303 | D | ↗ |
| 2024-12-19 | Henderson Molly | Officer | S-Sale | D | Common Stock | 1,291 | 8.00 | 10.3K | 98,156 | D | ↗ |
| 2024-12-13 | Parikh Asit | Director | P-Purchase | A | Common Stock | 10,000 | 8.12 | 81.2K | 75,500 | D | ↗ |
| 2024-12-13 | KARBE FRANK | Director | P-Purchase | A | Common Stock | 12,500 | 7.93 | 99.1K | 57,000 | D | ↗ |
| 2024-09-10 | Parikh Asit | Director | M-Exempt | A | Common Stock | 7,500 | 11.72 | 87.9K | 93,000 | D | ↗ |
| 2024-07-15 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 10,901 | 11.72 | 127.8K | 240,421 | — | ↗ |
| 2024-07-15 | Henderson Molly | Officer | S-Sale | D | Common Stock | 4,325 | 11.72 | 50.7K | 99,447 | — | ↗ |
| 2024-07-15 | Curran Terrie | Director / Officer | S-Sale | D | Common Stock | 33,848 | 11.72 | 396.7K | 377,734 | — | ↗ |
| 2024-05-31 | Nabulsi Azmi | Officer | A-Award | A | Common Stoock | 7,500 | 0.00 | — | 249,567 | — | ↗ |
| 2024-05-31 | Henderson Molly | Officer | A-Award | A | Common Stoock | 7,500 | 0.00 | — | 102,763 | — | ↗ |
| 2024-05-29 | KARBE FRANK | Director | A-Award | A | Common Stock | 25,000 | 10.16 | 254.1K | 44,500 | — | ↗ |
| 2024-05-23 | Topper James N | Director / 10% Owner | A-Award | D | Stock Option (Right to Buy) | 17,500 | 10.30 | 180.3K | 17,500 | — | ↗ |
| 2024-05-23 | Stenhouse Mark | Director | A-Award | D | Stock Option (Right to Buy) | 17,500 | 10.30 | 180.3K | 17,500 | — | ↗ |
| 2024-05-23 | Socks David A | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 19,500 | — | ↗ |
| 2024-05-23 | Parikh Asit | Director | A-Award | D | Stock Option (Right to Buy) | 17,500 | 10.30 | 180.3K | 17,500 | — | ↗ |
| 2024-05-23 | KARBE FRANK | Director | A-Award | D | Stock Option (Right to Buy) | 17,500 | 10.30 | 180.3K | 17,500 | — | ↗ |
| 2024-05-23 | FIELDS HEIDI | Director | A-Award | D | Stock Option (Right to Buy) | 17,500 | 10.30 | 180.3K | 17,500 | — | ↗ |
| 2024-05-23 | COLA MICHAEL F | Director | A-Award | A | Common Stock | 10,500 | 0.00 | — | 29,298 | — | ↗ |
| 2024-04-08 | Henderson Molly | Officer | S-Sale | D | Common Stoock | 3,435 | 11.10 | 38.1K | 95,263 | — | ↗ |
| 2024-03-22 | Curran Terrie | Director / Officer | S-Sale | D | Common Stock | 16,851 | 9.11 | 153.5K | 410,784 | — | ↗ |
| 2024-01-24 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 3,703,703 | 8.10 | 30.00M | 3,755,583 | — | ↗ |
| 2024-01-24 | Medicxi Ventures Management (Jersey) Ltd | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 87,267 | — | ↗ |
| 2024-01-19 | Henderson Molly | Officer | S-Sale | D | Common Stock | 6,307 | 7.75 | 48.9K | 98,698 | — | ↗ |
| 2024-01-18 | Nabulsi Azmi | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 7.60 | 988.0K | 130,000 | — | ↗ |
| 2024-01-18 | Henderson Molly | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 7.60 | 912.0K | 120,000 | — | ↗ |
| 2024-01-18 | Curran Terrie | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 475,000 | 7.60 | 3.61M | 475,000 | — | ↗ |
| 2023-11-20 | Henderson Molly | Officer | S-Sale | D | Common Stock | 2,127 | 7.24 | 15.4K | 103,061 | — | ↗ |
| 2023-11-08 | Parikh Asit | Director | P-Purchase | A | Common Stock | 2,500 | 7.80 | 19.5K | 55,000 | — | ↗ |
| 2023-11-07 | Parikh Asit | Director | P-Purchase | A | Common Stock | 4,000 | 7.76 | 31.0K | 52,500 | — | ↗ |
| 2023-11-06 | Parikh Asit | Director | P-Purchase | A | Common Stock | 1,000 | 8.04 | 8.0K | 48,500 | — | ↗ |
| 2023-11-01 | Nabulsi Azmi | Officer | A-Award | A | Common Stock | 32,500 | 0.00 | — | 242,067 | — | ↗ |
| 2023-11-01 | Henderson Molly | Officer | S-Sale | D | Common Stock | 11,681 | 8.95 | 104.5K | 105,188 | — | ↗ |
| 2023-11-01 | Curran Terrie | Director / Officer | A-Award | A | Common Stock | 37,500 | 0.00 | — | 427,171 | — | ↗ |
| 2023-07-14 | Nabulsi Azmi | Officer | D-Return | D | Stock Option | 70,000 | 32.20 | 2.25M | 0 | — | ↗ |
| 2023-07-14 | Henderson Molly | Officer | A-Award | A | Common Stock | 25,000 | 1.00 | 25.0K | 95,180 | — | ↗ |
| 2023-07-14 | Curran Terrie | Director / Officer | D-Return | D | Stock Option | 175,000 | 32.20 | 5.64M | 0 | — | ↗ |
| 2023-06-02 | Parikh Asit | Director | A-Award | A | Common Stock | 15,000 | 7.40 | 111.0K | 47,500 | — | ↗ |
| 2023-06-02 | Henderson Molly | Officer | S-Sale | D | Common Stock | 1,960 | 11.41 | 22.4K | 68,506 | — | ↗ |
| 2023-05-25 | Topper James N | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.72 | 175.8K | 15,000 | — | ↗ |
| 2023-05-25 | Stenhouse Mark | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2023-05-25 | Socks David A | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2023-05-25 | Parikh Asit | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 32,500 | — | ↗ |
| 2023-05-25 | KARBE FRANK | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2023-05-25 | FIELDS HEIDI | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2023-05-25 | COLA MICHAEL F | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.72 | 175.8K | 15,000 | — | ↗ |
| 2023-05-22 | Henderson Molly | Officer | S-Sale | D | Common Stock | 2,110 | 12.87 | 27.2K | 70,466 | — | ↗ |
| 2023-04-11 | Nabulsi Azmi | Officer | P-Purchase | A | Common Stock | 10,000 | 8.26 | 82.6K | 99,567 | — | ↗ |
| 2023-04-10 | Parikh Asit | Director | P-Purchase | A | Common Stock | 1,000 | 7.55 | 7.6K | 23,500 | — | ↗ |
| 2023-04-06 | Henderson Molly | Officer | S-Sale | D | Common Stock | 3,439 | 7.27 | 25.0K | 72,576 | — | ↗ |
| 2023-04-06 | Curran Terrie | Director / Officer | P-Purchase | A | Common Stock | 12,919 | 7.82 | 101.0K | 188,290 | — | ↗ |
| 2023-03-01 | Henderson Molly | Officer | S-Sale | D | Common Stock | 2,032 | 8.53 | 17.3K | 76,015 | — | ↗ |
| 2023-03-01 | Curran Terrie | Director / Officer | S-Sale | D | Common Stock | 1,436 | 8.54 | 12.3K | 175,371 | — | ↗ |
| 2023-02-13 | Parikh Asit | Director | P-Purchase | A | Common Stock | 5,000 | 7.73 | 38.7K | 22,500 | — | ↗ |
| 2023-01-20 | Curran Terrie | Officer | S-Sale | D | Common Stock | 5,821 | 8.20 | 47.7K | 176,807 | — | ↗ |
| 2023-01-19 | Nabulsi Azmi | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 89,567 | — | ↗ |
| 2023-01-19 | Henderson Molly | Officer | A-Award | A | Common Stock | 33,000 | 0.00 | — | 78,047 | — | ↗ |
| 2023-01-19 | Curran Terrie | Officer | A-Award | A | Common Stock | 97,500 | 0.00 | — | 182,628 | — | ↗ |
| 2023-01-12 | Parikh Asit | Director | P-Purchase | A | Common Stock | 5,000 | 7.00 | 35.0K | 17,500 | — | ↗ |
| 2022-11-21 | Henderson Molly | Officer | S-Sale | D | Common Stock | 2,159 | 9.60 | 20.7K | 43,341 | — | ↗ |
| 2022-11-21 | Curran Terrie | Officer | S-Sale | D | Common Stock | 1,526 | 9.60 | 14.6K | 83,720 | — | ↗ |
| 2022-09-22 | Topper James N | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy | 20,000 | 10.02 | 200.4K | 20,000 | — | ↗ |
| 2022-09-01 | Nabulsi Azmi | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 41,971 | — | ↗ |
| 2022-09-01 | Henderson Molly | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 45,500 | — | ↗ |
| 2022-09-01 | Curran Terrie | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 85,246 | — | ↗ |
| 2022-05-25 | Stenhouse Mark | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 7.40 | 111.0K | 15,000 | — | ↗ |
| 2022-05-25 | Socks David A | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-25 | Parikh Asit | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-25 | KARBE FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 7.40 | 74.0K | 10,000 | — | ↗ |
| 2022-05-25 | FIELDS HEIDI | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-25 | COLA MICHAEL F | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-19 | Nabulsi Azmi | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 33,378 | — | ↗ |
| 2022-05-19 | Henderson Molly | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 38,000 | — | ↗ |
| 2022-05-19 | Curran Terrie | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 76,595 | — | ↗ |
| 2022-05-16 | Nabulsi Azmi | Officer | P-Purchase | A | Common Stock | 20,000 | 8.16 | 163.3K | 785,700 | — | ↗ |
| 2022-05-13 | Henderson Molly | Officer | P-Purchase | A | Common Stock | 6,000 | 0.00 | — | 26,000 | — | ↗ |
| 2022-05-13 | Curran Terrie | Officer | P-Purchase | A | Common Stock | 20,500 | 7.41 | 151.8K | 64,595 | — | ↗ |
| 2022-05-12 | Parikh Asit | Director | P-Purchase | A | Common Stock | 12,500 | 8.00 | 100.0K | 12,500 | — | ↗ |
| 2022-04-25 | KARBE FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-04-05 | Henderson Molly | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-03-14 | TAKEDA PHARMACEUTICAL CO LTD | Director | S-Sale | D | Common Stock | 18 | 19.00 | 342.00 | 7,459,286 | — | ↗ |
| 2022-01-19 | Nabulsi Azmi | Officer | A-Award | A | Stock Option (Right to Buy) | 97,500 | 15.21 | 1.48M | 97,500 | — | ↗ |
| 2022-01-19 | Guzzo Anthony J. | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 15.21 | 456.3K | 30,000 | — | ↗ |
| 2022-01-19 | Curran Terrie | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-04 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 1 | 19.00 | 19.00 | 1,100,000 | — | ↗ |
| 2021-10-08 | Socks David A | Director | S-Sale | D | Common Stock | 2,529 | 32.05 | 81.1K | 1,211,346 | — | ↗ |
| 2021-10-07 | Socks David A | Director | S-Sale | D | Common Stock | 15,471 | 32.66 | 505.3K | 1,213,875 | — | ↗ |
| 2021-09-22 | Socks David A | Director | S-Sale | D | Common Stock | 4,100 | 32.06 | 131.4K | 1,229,346 | — | ↗ |
| 2021-09-21 | Socks David A | Director | S-Sale | D | Common Stock | 13,576 | 32.79 | 445.1K | 1,233,770 | — | ↗ |
| 2021-08-16 | Socks David A | Director | S-Sale | D | Common Stock | 4,209 | 30.47 | 128.2K | 1,261,137 | — | ↗ |
| 2021-07-13 | Parikh Asit | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 34.05 | 255.4K | 7,500 | — | ↗ |
| 2021-07-07 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 2,609 | 35.05 | 91.4K | 871,305 | — | ↗ |
| 2021-07-02 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 100 | 35.01 | 3.5K | 873,914 | — | ↗ |
| 2021-07-01 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 8,226 | 35.16 | 289.2K | 874,014 | — | ↗ |
| 2021-06-29 | Socks David A | Director | S-Sale | D | Common Stock | 13,960 | 34.00 | 474.7K | 1,260,945 | — | ↗ |
| 2021-06-28 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 370 | 35.08 | 13.0K | 882,240 | — | ↗ |
| 2021-06-28 | Socks David A | Director | S-Sale | D | Common Stock | 25,884 | 34.07 | 881.8K | 1,275,061 | — | ↗ |
| 2021-06-25 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 22,881 | 35.46 | 811.4K | 883,860 | — | ↗ |
| 2021-06-24 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 10,848 | 35.14 | 381.2K | 906,741 | — | ↗ |
| 2021-06-23 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 200 | 35.00 | 7.0K | 917,589 | — | ↗ |
| 2021-06-22 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 100 | 35.00 | 3.5K | 917,789 | — | ↗ |
| 2021-06-21 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 9,294 | 35.31 | 328.2K | 917,889 | — | ↗ |
| 2021-06-18 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 5,398 | 35.13 | 189.6K | 927,183 | — | ↗ |
| 2021-06-17 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 3,305 | 35.08 | 115.9K | 932,581 | — | ↗ |
| 2021-06-14 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 2,826 | 35.06 | 99.1K | 935,886 | — | ↗ |
| 2021-06-10 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 2,102 | 35.14 | 73.9K | 938,712 | — | ↗ |
| 2021-06-09 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 1,191 | 35.28 | 42.0K | 940,814 | — | ↗ |
| 2021-06-08 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 100 | 35.00 | 3.5K | 942,005 | — | ↗ |
| 2021-06-07 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 2,264 | 35.05 | 79.4K | 942,105 | — | ↗ |
| 2021-06-04 | Guzzo Anthony J. | Officer | — | D | Stock Option (Right to Buy) | 57,500 | 25.06 | 1.44M | 0 | — | ↗ |
| 2021-06-02 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 4,300 | 35.18 | 151.3K | 944,369 | — | ↗ |
| 2021-06-01 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 7,244 | 35.55 | 257.5K | 952,636 | — | ↗ |
| 2021-05-28 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 4,133 | 35.37 | 146.2K | 964,652 | — | ↗ |
| 2021-05-27 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 2,279 | 37.55 | 85.6K | 968,785 | — | ↗ |
| 2021-05-26 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 7,469 | 36.45 | 272.2K | 982,127 | — | ↗ |
| 2021-05-25 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 10,399 | 36.16 | 376.0K | 990,144 | — | ↗ |
| 2021-05-24 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 8,911 | 35.58 | 317.1K | 1,002,226 | — | ↗ |
| 2021-05-21 | Yamada Tadataka | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 35.49 | 443.6K | 12,500 | — | ↗ |
| 2021-05-21 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 11,648 | 35.74 | 416.3K | 1,011,137 | — | ↗ |
| 2021-05-21 | Stenhouse Mark | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 35.49 | 443.6K | 12,500 | — | ↗ |
| 2021-05-21 | Socks David A | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 35.49 | 443.6K | 12,500 | — | ↗ |
| 2021-05-21 | Parikh Asit | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 35.49 | 443.6K | 12,500 | — | ↗ |
| 2021-05-21 | FIELDS HEIDI | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 35.49 | 443.6K | 12,500 | — | ↗ |
| 2021-05-21 | COLA MICHAEL F | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 35.49 | 443.6K | 12,500 | — | ↗ |
| 2021-05-20 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 7,098 | 35.10 | 249.1K | 1,022,785 | — | ↗ |
| 2021-05-20 | Socks David A | Director | S-Sale | D | Common Stock | 305 | 35.27 | 10.8K | 1,300,945 | — | ↗ |
| 2021-05-19 | Socks David A | Director | S-Sale | D | Common Stock | 17,269 | 31.96 | 551.8K | 1,323,676 | — | ↗ |
| 2021-05-14 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 100 | 35.00 | 3.5K | 1,029,883 | — | ↗ |
| 2021-05-13 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 100 | 35.33 | 3.5K | 1,029,983 | — | ↗ |
| 2021-05-12 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 10,871 | 35.39 | 384.7K | 1,030,988 | — | ↗ |
| 2021-05-07 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 1,011 | 35.03 | 35.4K | 1,041,859 | — | ↗ |
| 2021-05-06 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 202 | 35.01 | 7.1K | 1,042,870 | — | ↗ |
| 2021-05-05 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 6,936 | 35.14 | 243.7K | 1,043,072 | — | ↗ |
| 2021-05-04 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 100 | 38.53 | 3.9K | 1,050,008 | — | ↗ |
| 2021-05-04 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 1,089 | 37.86 | 41.2K | 765,700 | — | ↗ |
| 2021-05-03 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | S-Sale | D | Common Stock | 203 | 39.06 | 7.9K | 1,069,368 | — | ↗ |
| 2021-05-03 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 4,290 | 37.85 | 162.4K | 775,910 | — | ↗ |
| 2021-04-06 | Socks David A | Director | S-Sale | D | Common Stock | 1,400 | 34.96 | 48.9K | 1,357,427 | — | ↗ |
| 2021-04-05 | Socks David A | Director | S-Sale | D | Common Stock | 1,730 | 37.15 | 64.3K | 1,358,827 | — | ↗ |
| 2021-04-05 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 4,252 | 35.66 | 151.6K | 785,301 | — | ↗ |
| 2021-04-01 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 3,405 | 37.28 | 126.9K | 791,295 | — | ↗ |
| 2021-03-22 | Curran Terrie | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,513 | 6.95 | 80.0K | 855,687 | — | ↗ |
| 2021-03-12 | Socks David A | Director | S-Sale | D | Common Stock | 500 | 46.67 | 23.3K | 1,380,945 | — | ↗ |
| 2021-03-11 | Socks David A | Director | S-Sale | D | Common Stock | 41,698 | 47.18 | 1.97M | 1,382,176 | — | ↗ |
| 2021-03-11 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | S-Sale | D | Common Stock | 710,000 | 43.75 | 31.06M | 3,115,008 | — | ↗ |
| 2021-03-10 | Socks David A | Director | S-Sale | D | Common Stock | 2,425 | 48.32 | 117.2K | 1,433,520 | — | ↗ |
| 2021-03-02 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 600 | 44.60 | 26.8K | 803,227 | — | ↗ |
| 2021-03-01 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 1,548 | 46.05 | 71.3K | 803,827 | — | ↗ |
| 2021-02-23 | Socks David A | Director | S-Sale | D | Common Stock | 1,019 | 42.50 | 43.3K | 1,439,910 | — | ↗ |
| 2021-02-22 | Socks David A | Director | S-Sale | D | Common Stock | 11,482 | 45.27 | 519.7K | 1,449,587 | — | ↗ |
| 2021-02-19 | Socks David A | Director | S-Sale | D | Common Stock | 21,360 | 47.08 | 1.01M | 1,479,385 | — | ↗ |
| 2021-02-02 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 2,700 | 40.51 | 109.4K | 815,584 | — | ↗ |
| 2021-02-01 | Nabulsi Azmi | Officer | S-Sale | D | Common Stock | 5,416 | 38.09 | 206.3K | 818,284 | — | ↗ |
| 2021-01-28 | Nabulsi Azmi | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 39.11 | 5.87M | 150,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-374.7K
Shares Outstanding
79.43M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Steven Basta President and Chief Executive Officer | 525.0K | — | 1.99M | 3.98M | 455.7K | 17.6K | 6.97M | 85.67% | ↗ |
| 2 | 2025 | Terrie Curran Former President and Chief Executive Officer | 184.0K | — | 473.5K | 1.45M | — | 2.83M | 4.94M | 38.87% | ↗ |
| 3 | 2025 | Sanjeev Narula Chief Financial and Business Officer | 131.4K | — | 1.67M | 1.73M | 81.5K | 7.2K | 3.62M | 93.92% | ↗ |
| 4 | 2025 | Azmi Nabulsi, M.D., M.P.H. Former Chief Operating Officer | 219.8K | — | 532.2K | 232.1K | — | 1.73M | 2.71M | 28.16% | ↗ |
| 5 | 2025 | Anne Marie Cook Chief Legal Officer and Secretary | 261.5K | — | 199.9K | 1.48M | 145.9K | 16.7K | 2.10M | 79.80% | ↗ |
| 6 | 2024 | Terrie Curran Former President and Chief Executive Officer | 708.1K | — | — | 2.47M | 368.2K | 17.3K | 3.56M | 69.32% | ↗ |
| 7 | 2024 | Azmi Nabulsi, M.D., M.P.H. Chief Operating Officer | 569.0K | — | 70.7K | 676.4K | 233.3K | 17.3K | 1.57M | 47.68% | ↗ |
| 8 | 2024 | Azmi Nabulsi, M.D., M.P.H. Former Chief Operating Officer | 569.0K | — | 70.7K | 676.4K | 233.3K | 17.3K | 1.57M | 47.68% | ↗ |
| 9 | 2024 | Molly Henderson Chief Financial and Business Officer | 515.0K | — | 70.7K | 624.3K | 197.0K | 17.3K | 1.42M | 48.80% | ↗ |
| 10 | 2023 | Terrie Curran President and Chief Executive Officer | 687.5K | — | 1.36M | 830.5K | 518.2K | 16.9K | 3.41M | 64.16% | ↗ |
| 11 | 2023 | Terrie Curran Former President and Chief Executive Officer | 687.5K | — | 1.36M | 830.5K | 518.2K | 16.9K | 3.41M | 64.16% | ↗ |
| 12 | 2023 | Azmi Nabulsi, M.D., M.P.H. Chief Operating Officer | 552.0K | — | 763.7K | 383.3K | 320.0K | 16.9K | 2.04M | 56.34% | ↗ |
| 13 | 2023 | Molly Henderson Chief Financial and Business Officer | 500.0K | — | 814.9K | 281.1K | 260.9K | 16.9K | 1.87M | 58.49% | ↗ |
| 14 | 2022 | Terrie Curran President and Chief Executive Officer | 650.0K | — | — | 3.93M | 442.4K | 15.4K | 5.04M | 78.02% | ↗ |
| 15 | 2022 | Azmi Nabulsi, M.D., M.P.H. Chief Operating Officer | 525.0K | — | — | 1.95M | 274.8K | 15.4K | 2.76M | 70.49% | ↗ |
| 16 | 2022 | Molly Henderson Chief Financial and Business Officer | 356.6K | 75.0K | — | 1.98M | 226.2K | 13.5K | 2.65M | 74.66% | ↗ |
| 17 | 2022 | Molly Henderson Chief Accounting Officer | 356.6K | 75.0K | — | 1.98M | 226.2K | 13.5K | 2.65M | 74.66% | ↗ |
| 18 | 2021 | Terrie Curran President and Chief Executive Officer | 567.5K | — | — | 5.29M | 396.3K | 14.6K | 6.27M | 84.40% | ↗ |
| 19 | 2021 | Azmi Nabulsi, M.D., M.P.H. Chief Operating Officer | 491.3K | — | — | 3.53M | 285.8K | 14.6K | 4.32M | 81.68% | ↗ |
| 20 | 2021 | Anthony Guzzo Chief Accounting Officer | 319.3K | 22.9K | 326.3K | 570.6K | 111.5K | 14.6K | 1.37M | 65.70% | ↗ |
| 21 | 2020 | Terrie Curran President and Chief Executive Officer | 498.9K | — | 483.0K | 3.29M | 356.9K | 10.0K | 4.63M | 81.32% | ↗ |
| 22 | 2020 | Azmi Nabulsi, M.D., M.P.H. Chief Operating Officer | 445.1K | — | — | 1.31M | 268.3K | 14.6K | 2.36M | 55.59% | ↗ |
| 23 | 2020 | Todd P. Branning Chief Financial Officer | 190.6K | — | 294.3K | 1.46M | 99.8K | 6.4K | 2.05M | 85.51% | ↗ |
| 24 | 2019 | Terrie Curran President and Chief Executive Officer | 41.7K | — | — | 3.39M | 23.1K | — | 3.46M | 98.13% | ↗ |
| 25 | 2019 | David Socks Chief Financial Officer | 331.7K | — | — | — | 197.6K | 12.8K | 542.1K | 0.00% | ↗ |
| 26 | 2019 | Azmi Nabulsi, M.D., M.P.H. Chief Operating Officer | 388.5K | — | — | — | 142.5K | — | 531.0K | 0.00% | ↗ |
| 27 | 2019 | Aditya Kohli, Ph.D. Chief Business Officer | 194.1K | — | — | — | 80.0K | 6.7K | 280.8K | 0.00% | ↗ |
| 28 | 2018 | David Socks Chief Financial Officer | 153.3K | — | — | — | — | 16.8K | 170.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David A. Socks | Co-Founder | 2M | male |
| Azmi Nabulsi | Co-Founder | 2M | — |
| Steven L. Basta | Chief Executive Officer, President & Director | 1M | male |
| Anne Marie Cook | Chief Legal Officer & Corporate Secretary | 663.4K | female |
| Sanjeev Narula | Chief Financial & Business Officer | 644.3K | male |
| Eric Sciorilli | Director of Business Development & Investor Relations | — | male |
| Jay Buchanan | Senior VP of Manufacturing & Supply Chain | — | — |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations & Training | — | male |
| Nancy R. Phelan | Senior Vice President of Marketing & Analytics | — | female |
| Paul Cocja | Chief People Officer | — | male |
| Robert Breedlove | Vice President of Finance & Principal Accounting Officer | — | male |
| Eckhard Leifke | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHAT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
